Observational Study on Oropharyngeal Carcinoma

This study aims to better understand oropharyngeal carcinoma (OPC), a type of throat cancer, and its connection to the human papilloma virus (HPV). Researchers will collect blood samples from patients with OPC before they start treatment and at six different times afterward. The goal is to learn more about how this cancer develops and changes over time. You may be able to join if you are 18 or older and have been diagnosed with oropharyngeal carcinoma, or a cancer of unknown origin that is linked to HPV or thought to be from the oropharynx. This is an observational study, meaning no specific interventions or treatments are being tested.

Study design
This is an observational study with a planned enrollment of 1000 participants. It is not a treatment study, but rather focuses on collecting information.
What's involved
Participants will have blood collected prior to starting treatment and at six subsequent time points.
Compensation
Not stated in the trial record.
Follow-up
Blood samples will be collected for up to 36 months after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05880797

Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma

Recruiting
Not specifiedAges 18+Observational
Stanford University
~1,000 participants
Updated 2026-04-13 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sample collection
Measured over prior to start of treatment
+1 more outcome measured
Oropharyngeal Carcinoma
Human Papilloma Virus
1 sites across 1 states
California1
  • Chris Holsinger, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients diagnosed with oropharyngeal carcinoma or patients with cancer of the unknown primary that is HPV associated, or possibly deemed to be originating from the oropharynx.

Exclusion

Not willing to sign consent
  • Sample collectionprior to start of treatment

    30-50cc of blood

  • Sample collectionup to 36 months post-op

    30-50cc of blood